ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Esomeprazole

Also written as “esomeprazole”, “PN400” and “Esomeprazole (Nexium)”.

Its studies are mostly in Gastroesophageal Reflux · Stomach Ulcer · Heartburn · Esophagitis, Peptic · Gastrointestinal Diseases, led by 15 companies.

Drug pageEsomeprazole: every studyMany companies study it; this page follows only the 122 they lead. All 244 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 12, 2005122 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only920 open or runningphase 4since Sep 12, 2005Mar 16, 2004none ahead
Hanmi Pharmaceuticalits history only50 open or runningphase 3since Sep 4, 2019Dec 8, 2017none ahead
Aralez Pharmaceuticalsits history only40 open or runningphase 1since Jan 11, 2008Jan 11, 2008none ahead
Chong Kun Dang Pharmaceuticalits history only30 open or runningphase 1since Feb 6, 2018Feb 6, 2018none ahead
Pfizer30 open or runningphase 4since Jan 21, 2016Feb 25, 2012none ahead
Takedaits history only30 open or runningphase 2since Apr 14, 2016Jul 16, 2009none ahead
Torrent Pharmaceuticalsits history only30 open or runningphase 1since Nov 9, 2015Nov 9, 2015none ahead
EMSits history only20 open or runningphase 4since Sep 2, 2015Sep 2, 2015none ahead
Elpen Pharmaceuticalits history only10 open or runningphase 4since Nov 7, 2016Nov 7, 2016none ahead
Eurofarma Laboratoriosits history only10 open or runningphase 3since Oct 31, 2011Oct 31, 2011none ahead

Also a collaborator on its studies: IQVIA RDS, Laboratory Corporation of America, Medidata Solutions, Thermo Fisher Scientific, CISCRP, Arvinas Estrogen Receptor, Parexel and Quintiles.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 25, 2012First study: phase 1 study in HealthyFirst studyNCT01549574 · 16 enrolled · Belgium
  2. Jan 21, 2016Phase 4 study in HeartburnNCT02708355 · 55 enrolled · United States
  3. Feb 16, 2024Phase 1 study in HealthyNCT06275841 · 12 enrolled · United States

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
RabeprazoleruleEisaiphase 466
OmeprazoleruleAstraZenecaphase 456
tegoprazanruleHK inno.Nphase 448
vonoprazanruleTakedaphase 448
fexuprazanruleDaewoong Pharmaceuticalphase 429

Studies

All 3 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06275841Healthy · United States1CompletedMay 3, 202412
NCT02708355Heartburn · United States4CompletedApr 201655
NCT01549574Healthy · Belgium1CompletedMay 201216

How it is read

Names in the registry

  • “Esomeprazole”, 72 entries
  • “esomeprazole”, 8 entries
  • “PN400”, 8 entries
  • “Esomeprazole (Nexium)”, 3 entries
  • “HIP1601”, 3 entries

Codes read as this program: D961H, D026.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.